Cite
MLA Citation
James D. Lewis et al.. “S851 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn's Disease: PROMIS-29 in the SEAVUE Study.” American journal of gastroenterology, vol. 116, n.d., p. S395. http://access.bl.uk/ark:/81055/vdc_100144524038.0x000031